| pubmed-article:11509930 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11509930 | lifeskim:mentions | umls-concept:C1257890 | lld:lifeskim |
| pubmed-article:11509930 | lifeskim:mentions | umls-concept:C0337810 | lld:lifeskim |
| pubmed-article:11509930 | lifeskim:mentions | umls-concept:C0005961 | lld:lifeskim |
| pubmed-article:11509930 | lifeskim:mentions | umls-concept:C0023467 | lld:lifeskim |
| pubmed-article:11509930 | lifeskim:mentions | umls-concept:C0025241 | lld:lifeskim |
| pubmed-article:11509930 | lifeskim:mentions | umls-concept:C1274040 | lld:lifeskim |
| pubmed-article:11509930 | lifeskim:mentions | umls-concept:C1521725 | lld:lifeskim |
| pubmed-article:11509930 | lifeskim:mentions | umls-concept:C1831743 | lld:lifeskim |
| pubmed-article:11509930 | lifeskim:mentions | umls-concept:C0936012 | lld:lifeskim |
| pubmed-article:11509930 | lifeskim:mentions | umls-concept:C1514923 | lld:lifeskim |
| pubmed-article:11509930 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:11509930 | pubmed:dateCreated | 2001-8-17 | lld:pubmed |
| pubmed-article:11509930 | pubmed:abstractText | This retrospective study from the Italian Association of Pediatric Hematology Oncology-Bone Marrow Transplant Group (AIEOP-TMO) reports the results of consolidation with high-dose melphalan and autologous hematopoietic stem cell transplantation (auto-HSCT) in patients with acute myeloid leukemia (AML) in first complete remission (CR1). From October 1994 to July 1999, 20 patients (median age 9.9 years, range 0.11-16.2) were treated in six centers. Eighteen had de novo AML and two had secondary AML. According to BFM criteria, 10 were classified as standard- and 10 as high-risk patients, respectively. The median time from diagnosis to CR1 and from diagnosis to Auto-HSCT were 1.1 months (range 0.8-1.6) and 4.3 months (range 3.1-6.2), respectively. Purging with either mafosfamide (three) or in vivo interleukin-2 (four) was performed in seven of 20 patients. Melphalan was administered at a dosage of 150-220 mg/m(2) (median 180). Median total number of nucleated cells infused was 2.5 x 10(8)/kg (range 1.1-8.9). The myeloablative regimen was well tolerated with no toxic death, veno-occlusive disease or life-threatening complications. All patients had hematopoietic recovery in a median time of 27 days for neutrophils and 44 days for platelets. Eight of 20 patients relapsed after a median time of 7.2 months from transplant (range 5.7-15.9). Six of them died (five of progression of disease and one of sepsis) while the remaining two patients are alive in CR2. The 3-year cumulative probability of survival and event-free-survival (EFS) is 62% and 56%, respectively. This study showed that in pediatric patients with AML consolidation of CR1 with high-dose melphalan allows survival and EFS to be obtained comparable to other auto-HSCT or chemotherapy published series with a potential sparing effect both on duration of treatment (with respect to chemotherapy) and on long-term side-effects (with respect to auto-HSCT with TBI or busulfan containing regimens). | lld:pubmed |
| pubmed-article:11509930 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11509930 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11509930 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11509930 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11509930 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11509930 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11509930 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11509930 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11509930 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11509930 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:11509930 | pubmed:issn | 0268-3369 | lld:pubmed |
| pubmed-article:11509930 | pubmed:author | pubmed-author:LocatelliFF | lld:pubmed |
| pubmed-article:11509930 | pubmed:author | pubmed-author:MessinaCC | lld:pubmed |
| pubmed-article:11509930 | pubmed:author | pubmed-author:PillonMM | lld:pubmed |
| pubmed-article:11509930 | pubmed:author | pubmed-author:MeloniGG | lld:pubmed |
| pubmed-article:11509930 | pubmed:author | pubmed-author:CaniggiaMM | lld:pubmed |
| pubmed-article:11509930 | pubmed:author | pubmed-author:CesaroSS | lld:pubmed |
| pubmed-article:11509930 | pubmed:author | pubmed-author:BagnuloSS | lld:pubmed |
| pubmed-article:11509930 | pubmed:author | pubmed-author:PessionAA | lld:pubmed |
| pubmed-article:11509930 | pubmed:author | pubmed-author:LaninoEE | lld:pubmed |
| pubmed-article:11509930 | pubmed:author | pubmed-author:ProgliaAA | lld:pubmed |
| pubmed-article:11509930 | pubmed:author | pubmed-author:Italian... | lld:pubmed |
| pubmed-article:11509930 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11509930 | pubmed:volume | 28 | lld:pubmed |
| pubmed-article:11509930 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11509930 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11509930 | pubmed:pagination | 131-6 | lld:pubmed |
| pubmed-article:11509930 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:11509930 | pubmed:meshHeading | pubmed-meshheading:11509930... | lld:pubmed |
| pubmed-article:11509930 | pubmed:meshHeading | pubmed-meshheading:11509930... | lld:pubmed |
| pubmed-article:11509930 | pubmed:meshHeading | pubmed-meshheading:11509930... | lld:pubmed |
| pubmed-article:11509930 | pubmed:meshHeading | pubmed-meshheading:11509930... | lld:pubmed |
| pubmed-article:11509930 | pubmed:meshHeading | pubmed-meshheading:11509930... | lld:pubmed |
| pubmed-article:11509930 | pubmed:meshHeading | pubmed-meshheading:11509930... | lld:pubmed |
| pubmed-article:11509930 | pubmed:meshHeading | pubmed-meshheading:11509930... | lld:pubmed |
| pubmed-article:11509930 | pubmed:meshHeading | pubmed-meshheading:11509930... | lld:pubmed |
| pubmed-article:11509930 | pubmed:meshHeading | pubmed-meshheading:11509930... | lld:pubmed |
| pubmed-article:11509930 | pubmed:meshHeading | pubmed-meshheading:11509930... | lld:pubmed |
| pubmed-article:11509930 | pubmed:meshHeading | pubmed-meshheading:11509930... | lld:pubmed |
| pubmed-article:11509930 | pubmed:meshHeading | pubmed-meshheading:11509930... | lld:pubmed |
| pubmed-article:11509930 | pubmed:meshHeading | pubmed-meshheading:11509930... | lld:pubmed |
| pubmed-article:11509930 | pubmed:meshHeading | pubmed-meshheading:11509930... | lld:pubmed |
| pubmed-article:11509930 | pubmed:meshHeading | pubmed-meshheading:11509930... | lld:pubmed |
| pubmed-article:11509930 | pubmed:meshHeading | pubmed-meshheading:11509930... | lld:pubmed |
| pubmed-article:11509930 | pubmed:meshHeading | pubmed-meshheading:11509930... | lld:pubmed |
| pubmed-article:11509930 | pubmed:meshHeading | pubmed-meshheading:11509930... | lld:pubmed |
| pubmed-article:11509930 | pubmed:meshHeading | pubmed-meshheading:11509930... | lld:pubmed |
| pubmed-article:11509930 | pubmed:meshHeading | pubmed-meshheading:11509930... | lld:pubmed |
| pubmed-article:11509930 | pubmed:year | 2001 | lld:pubmed |
| pubmed-article:11509930 | pubmed:articleTitle | High-dose melphalan with autologous hematopoietic stem cell transplantation for acute myeloid leukemia: results of a retrospective analysis of the Italian Pediatric Group for Bone Marrow Transplantation. | lld:pubmed |
| pubmed-article:11509930 | pubmed:affiliation | Clinica di Oncoematologia Pediatrica, Dipartimento di Pediatria, Università di Padova, Italy. | lld:pubmed |
| pubmed-article:11509930 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11509930 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:11509930 | pubmed:publicationType | Multicenter Study | lld:pubmed |
